PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Treatment News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.

June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By Anonymous User anonymous_user_10987

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, treatment


First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By Anonymous User anonymous_user_10987

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


Managing Side Effects From EGFR Inhibitors

April 10, 2018

Managing Side Effects From EGFR Inhibitors

By Anonymous User anonymous_user_10987

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs and these cause similar side effects. The EGFR pathway is a normal biologic pathway found in […]

View full entry

Tags: cetuximab, Colon Cancer, diarrhea, EGFR inhibitors, erbitux, Erlotinib, Gefitinib, Head and Neck Cancer, iressa, Lung Cancer, News Tips and Features, News Tips and Features Other


Pamrevlumab Awarded "Fast Track" Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News Tips and Features, News Tips and Features Other, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Precision Cancer Medicine, treatment


View more articles like this
More news and in-depth Pancreatic Cancer information

CONDITIONS OF THE GI TRACT